Alacris Theranostics GmbH : Alacris Theranostics GmbH Announces Illumina CSPro Certification for Next Generation Sequencing

Alacris Theranostics GmbH : Alacris Theranostics GmbH Announces Illumina CSPro
                 Certification for Next Generation Sequencing

Alacris Theranostics GmbH / Alacris Theranostics GmbH Announces Illumina CSPro
Certification for Next Generation Sequencing . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this
announcement.

Berlin, Germany, June  11, 2013  - Alacris Theranostics  GmbH announced  today 
that it has successfully completed  Illumina CSPro(TM) certification for  next 
generation sequencing  (NGS);  gaining  entry  to an  elite  global  group  of 
Illumina genomics service providers. Illumina Inc., a San Diego-based company,
provides leading-edge genetic analysis tools to genomics centers worldwide.

Illumina CSPro is the collaborative service provider partnership dedicated  to 
ensuring the  delivery  of  the highest-quality  data  available  for  genetic 
analysis  applications.  Illumina  CSPro   participants  undergo  a   rigorous 
two-phase certification process  that includes minimum  data generation,  data 
certification, and an on-site audit of the facility and processes.

"Alacris Theranostics  is  advancing the  field  of personalised  medicine  by 
developing new approaches for the prediction  of drug treatments. To this  end 
the company is applying its proprietary systems biology model, ModCell(TM) for
use in  drug development  projects for  Pharma and  patient stratification  in 
clinical research projects.  For the development  of ModCell(TM) high  quality 
NGS data provided for example through the Illumina technology is the basis for
precise modelling predictions. Alacris also provides expertise in  sequencing, 
analysis   and    mathematical    modelling   within    global    personalised 
medicine-oriented  projects   (for  example   OncoTrack   (www.oncotrack.eu)). 
Becoming an  Illumina  CSPro  for  NGS is  valuable  confirmation  of  Alacris 
Theranostics'  excellent  management,   laboratory  and  analysis   standards, 
important for both the company and its clients."

"Illumina  CSPro  recognizes   organizations  that   provide  customers   with 
industry-leading data quality  and service  in genetic  analysis," said  Karen 
Possemato, Illumina's Sr.  Director of Corporate  Marketing. Now that  Alacris 
Theranostics is a global CSPro  partner, we are excited  to work with them  to 
make it easier for  researchers in Germany to  access the power of  Illumina's 
genetic analysis technologies."

About Alacris Theranostics
Alacris Theranostics GmbH is a Berlin-based company specialising in the
development of new personalised medicine approaches for cancer patient
diagnosis, treatment and drug stratification. Using its proprietary virtual
patient model ModCell(TM) Alacris can perform personalised prediction of drug
treatments, supporting its clients for drug development and in clinical trials
by matching patients to therapies and therapies to patients. The Alacris
Theranostics team has a strong background in academic cancer research and
collaborates closely with oncologists and pharmaceutical companies worldwide.
It also possesses extensive expertise in all aspects of NGS, from initial
experimental design through to the comprehensive analysis of sequence data,
offering this service also for a wide range of applications, including whole
genome and targeted sequencing, ChIP-Seq, RNA-Seq and microRNA/small RNA
analysis of (clinical) tumor and normal tissue samples.

Contact:
Alacris Theranostics GmbH
Dr. B. Lange
Fabeckstrasse 60-62
D-14195 Berlin

Phone: +49 30 8413-1471
Fax: +49 30 8413-1465
Email: info@alacris.de
Web: www.alacris.de

MC Services AG
Anne Hennecke, Managing Partner
Phone: +49 89 210 228 18
Email: anne.hennecke@mc-services.eu

Press release (PDF)

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Alacris Theranostics GmbH via Thomson Reuters ONE
HUG#1708507

--- End of Message ---

Alacris Theranostics GmbH
Fabeckstrasse 60-62 Berlin Germany
 
Press spacebar to pause and continue. Press esc to stop.